Abstract
Background and objective: As aging is associated with physiological changes, including renal and hepatic insufficiency, and a higher risk of drug interactions, special attention needs to be directed towards the safety of medications in the elderly. The objective of this analysis was to evaluate the safety of oral moxifloxacin in elderly patients who were enrolled in clinical trials and to compare these results to those of other commonly used antibacterials.
Methods: Safety data from 27 prospective, randomised, comparative phase II/III trials of oral moxifloxacin included in the Bayer clinical trial database were pooled and analysed by age group (<65 years of age, 65–74 years of age, ≥75 years of age) and by treatment group (moxifloxacin vs comparator). The primary endpoints included rates of treatment-emergent adverse events (all adverse events regardless of causality), drug-related adverse events, drug-related serious adverse events, deaths and premature discontinuations because of a treatment-emergent adverse event. A treatment by age group interaction test was used to determine if the comparison between moxifloxacin and the comparator group in the incidence rates of any treatment-emergent or drug-related adverse events were affected by increasing age.
Results: Of the 12 231 patients who had valid safety data, 6270 had been treated with oral moxifloxacin and 5961 with a comparator antibacterial. The most frequently used comparators were cefuroxime and clarithromycin. Most patients (n = 9671) were <65 years of age (4939 moxifloxacin, 4732 comparator); 1636 patients were 65–74 years of age (842 moxifloxacin, 794 comparator); and 924 patients were ≥75 years of age (489 moxifloxacin, 435 comparator). The treatment by age group interaction test revealed that the comparison of drug-related adverse event rates between the moxifloxacin and comparator group were not affected by increasing age (p = 0.43). Rates of premature termination between the moxifloxacin and comparator treatment groups also did not increase with age (p = 0.552). No arrhythmias related to corrected QT (QTc) interval prolongation were reported following oral moxifloxacin or comparator treatment in this large group of young and elderly patients. Overall, the number of deaths was similar between the treatment groups (17 moxifloxacin, 19 comparator).
Conclusions: Drug-related adverse event rates associated with oral moxifloxacin or the comparator therapy used in these studies did not significantly increase with advancing age. This pooled analysis suggests that oral moxifloxacin can be safely used in elderly patients with characteristics consistent with those enrolled into the clinical trials.
Similar content being viewed by others
References
Yoshikawa TT, Norman DC. Treatment of infections in elderly patients. Med Clin North Am 1995; 79: 651–61
Andriole VT. The quinolones: prospects. In: Andriole VT, editor. The quinolones. San Diego: Academic Press, 2000: 477–495
Quintiliani R, Owens Jr RC, Grant EM. Clinical role of fluoroquinolones in patients with respiratory tract infections. Infect Dis Clin Pract 1999; 8Suppl. 1: S28–41
Blondeau JM. A review of the comparative in vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones. J Antimicrob Chemother 1999; 43Suppl. B: 1–11
Kim M-K, Nightingale CH. The quinolones: pharmacokinetics and pharmacodynamics of the fluoroquinolones. In: Andriole VT, editor. The quinolones. San Diego: Academic Press, 2000: 169–202
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41
Stass H, Kubitza D, von Bergmann K, Halabi A, Kuhlmann J, Sudhop T. No dose adjustment is needed for patients with hepatic impairment receiving oral moxifloxacin [abstract]. ECCMID 1999: P0771
Data on file, Bayer Pharmaceuticals, 1996–2001
Stass H, Kubitza D. Profile of moxifloxacin drug interactions. Clin Infect Dis 2001; 32Suppl. 1: S47–50
Gavin JR, Kubin R, Choudhri S, et al. Moxifloxacin and glucose homeostasis: evidence from pooled clinical and postmarketing studies. Drug Saf 2004; 27: 671–86
Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 2: 719–48
Agesti A. Analysis of ordinal categorical data. New York: John Wiley & Sons Inc, 1984
Wirtz M, Kleeff J, Swoboda S, et al. Moxifloxacin penetration into human gastrointestinal tissues. J Antimicrob Chemother 2004; 53: 875–7
Breilh D, Jougon J, Djabarouti S, et al. Diffusion of oral and intravenous 400mg once-daily moxifloxacin into lung tissue at pharmacokinetic steady-state. J Chemother 2003; 15: 558–62
Dinis PB, Monteiro MC, Martins ML, et al. Sinus tissue concentration of moxifloxacin after a single oral dose. Ann Otol Rhinol Laryngol 2004; 113: 142–6
Tillotson GS, Rybak J. New milestones achieved in fluoroquinolone safety. Pharmacotherapy 2001; 21: 358–60
Church D, Haverstock D, Andriole VT. Moxifloxacin: a review of its safety profile based on worldwide clinical trials. Today’s Therapeutic Trends 2000; 18: 205
Culley CM, Lacy MK, Klutman N, et al. Moxifloxacin: clinical efficacy and safety. Am J Health Syst Pharm 2001; 58: 379–88
Iannini PB, Kubin R, Reiter C, et al. Reassuring safety profile of moxifloxacin. Clin Infect Dis 2001; 32: 1112–4
Iannini PB, Mandell LA. An updated safety profile of moxifloxacin. J Chemother 2002; 14Suppl. 2: 29–34
Carbon C. Comparison of side effects of levofloxacin versus other fluoroquinolones. Chemotherapy 2001; 47Suppl. 3: 9–14
Gantz NM. Quinolones: their uses in geriatric infections. Geriatrics 1988; 43: 41–44, 47
Heyd A, Haverstock D. Retrospective analysis of the safety profile of oral and intravenous ciprofloxacin in a geriatric population. Clin Ther 2000; 22: 1239–50
Fostini R, Girelli M, Dalle Vedove P, et al. Safety profile of ofloxacin in elderly patients. Drugs Exp Clin Res 1988; 14: 393–5
File Jr TM, Tan JS. The use of oral fluoroquinolones in nursing home patients. Drugs Aging 1992; 2: 310–29
McCue JD. Rationale for the use of oral fluoroquinolones as empiric treatment of nursing home infections. Arch Fam Med 1994; 3: 157–64
Bertino Jr J, Fish D. The safety profile of the fluoroquinolones. Clin Ther 2000; 22: 798–817
Nicolle LE. Quinolones in the aged. Drugs 1999; 58Suppl. 2: 49–51
Acknowledgements
The data presented in this manuscript was presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, US (September 2002). This work was supported by a research grant from Bayer Pharmaceuticals Corporation, West Haven, Connecticut, US. We thank Brian G. Shearer, PhD and Teresa Tartaglione, PharmD for editorial contributions.
Daniel C. Haverstock and Shurjeel H. Choudhri are employed by Bayer Pharmaceuticals Corporation. Vincent T. Andriole has no conflicts of interest relevant to the content of this study.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Andriole, V.T., Haverstock, D.C. & Choudhri, S.H. Retrospective Analysis of the Safety Profile of Oral Moxifloxacin in Elderly Patients Enrolled in Clinical Trials. Drug-Safety 28, 443–452 (2005). https://doi.org/10.2165/00002018-200528050-00007
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-200528050-00007